{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:38:21Z","timestamp":1792805901329,"version":"4.5.0"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Small Animal Practice"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the median survival time (MST) of dogs with nasal carcinoma treated with toceranib phosphate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>The databases of four Spanish referral hospitals were retrospectively searched for dogs with a diagnosis of nasal tumours presented between January 2015 and October 2020. Dogs treated with radiotherapy or other chemotherapies prior toceranib were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty\u2010three dogs with a confirmed nasal carcinoma treated with toceranib phosphate and with a CT scan for initial staging according to Adams Modified Staging System were included. Nine dogs had a stage III nasal carcinoma whereas 14 dogs had a stage IV nasal carcinoma. No dog had stages I and II nasal carcinoma. The median overall survival time was 139\u2009days. The difference between the MST between dogs with stages III and IV was not statistically significant [P = 0.6, 140\u2009days for stage III (range 46\u2013401)\n                      <jats:italic>vs<\/jats:italic>\n                      120\u2009days for stage IV (range 23\u2013600)]. Overall, dogs with epistaxis achieved a longer median survival (166\u2009days) than dogs without epistaxis (83\u2009days). Toceranib phosphate was generally well tolerated. Most dogs had an initial clinical benefit followed by progressive disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>This is the first study to report the MST in dogs with stages III and IV nasal carcinoma treated with toceranib phosphate. This retrospective study showed that toceranib phosphate decreases the clinical signs associated with nasal carcinomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jsap.13387","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T04:15:21Z","timestamp":1623816921000},"page":"881-885","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of advanced\u2010stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015\u20132020)"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1791-2498","authenticated-orcid":false,"given":"V.","family":"Merino\u2010Gutierrez","sequence":"first","affiliation":[{"name":"Department of Internal Medicine AniCura Ars Veterinaria Hospital Veterinari Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"Borrego","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Hospital A\u00fana Especialidades Veterinarias Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4043-9395","authenticated-orcid":false,"given":"J.","family":"Puig","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine AniCura Ars Veterinaria Hospital Veterinari Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Hospital Veterinario Vetsia Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4631-4537","authenticated-orcid":false,"given":"F.","family":"Clemente\u2010Vicario","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine AniCura Ars Veterinaria Hospital Veterinari Barcelona Spain"},{"name":"Department of Medical Oncology Hospital Veterinario Vetsia Madrid Spain"},{"name":"Department of Medical Oncology La Merced Oncolog\u00eda Veterinaria Calpe Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1740-8261.2009.01545.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2010.00243.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1746-6148-9-190"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.5326\/0440116"},{"issue":"3","key":"e_1_2_5_6_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2460\/javma.1992.200.03.355","article-title":"Clinical response of nasal adenocarcinoma to cisplatin chemotherapy in 11 dogs","volume":"200","author":"Hahn K. A.","year":"1992","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1998.tb02147.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2017.07.030"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.70.207"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-0813.2004.tb12151.x"},{"key":"e_1_2_5_11_1","first-page":"2755","article-title":"Phase I dose\u2010 escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies","volume":"9","author":"London C. A.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1860"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2011.00275.x"},{"issue":"1","key":"e_1_2_5_14_1","first-page":"45","article-title":"Nasal tumors in the dog: retrospective evaluation of diagnosis, prognosis, and treatment","volume":"170","author":"MacEwen E. G.","year":"1977","journal-title":"Journal of the American Veterinary Medical Association"},{"issue":"7","key":"e_1_2_5_15_1","first-page":"851","article-title":"Neoplasm of the nasal passages and paranasal sinuses in domesticated animals as reported by 13 veterinary colleges","volume":"37","author":"Madawell B. R.","year":"1976","journal-title":"American Journal of Veterinary Research"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.10-0194"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsap.12083"},{"issue":"1","key":"e_1_2_5_18_1","first-page":"103","article-title":"Canine sinonasal neoplasm: clinicopathological study of 285 cases","volume":"25","author":"Patnaik A. K.","year":"1989","journal-title":"Journal of the American Animal Hospital Association"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.229.3.401"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/vru.12899"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.18-0347"},{"key":"e_1_2_5_22_1","first-page":"2495","article-title":"New response evaluation criteria in solid tumours\u2010revised RECIST guideline","volume":"36","author":"Watanabe H.","year":"2009","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12443"}],"container-title":["Journal of Small Animal Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jsap.13387","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jsap.13387","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jsap.13387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T18:17:23Z","timestamp":1725214643000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jsap.13387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/jsap.13387"],"URL":"https:\/\/doi.org\/10.1111\/jsap.13387","archive":["Portico"],"relation":{},"ISSN":["0022-4510","1748-5827"],"issn-type":[{"value":"0022-4510","type":"print"},{"value":"1748-5827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,16]]},"assertion":[{"value":"2021-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}